Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo
Version of Record online: 27 JAN 2006
Journal of the European Academy of Dermatology and Venereology
Volume 20, Issue 3, pages 269–273, March 2006
How to Cite
Kumaran, M., Kaur, I. and Kumar, B. (2006), Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. Journal of the European Academy of Dermatology and Venereology, 20: 269–273. doi: 10.1111/j.1468-3083.2006.01420.x
- Issue online: 27 JAN 2006
- Version of Record online: 27 JAN 2006
- Received: 23 August 2004, accepted: 2 November 2004; DOI: 10.1111/j.1468-3083.2006.01420.x
- betamethasone dipropionate;
- localized vitiligo
Background Treatment of vitiligo is a challenge. Steroids are known to be effective but are associated with serious adverse effects. Many uncontrolled studies have shown calcipotriol to be a promising therapeutic modality in vitiligo.
Objective To conduct a randomized trial to evaluate the effect of topical calcipotriol ointment (0.005%) and betamethasone dipropionate (0.05%) cream, given alone or in combination, in treatment of localized vitiligo.
Methods Forty-nine patients with vitiligo affecting 5% of their skin were recruited. Patients were randomized into three groups. Group I patients were treated with betamethasone dipropionate (0.05%) cream twice daily. Group II patients were treated with calcipotriol ointment (0.005%) twice daily, and group III with betamethasone dipropionate (0.05%) in the morning and calcipotriol (0.005%) in the evening.
Results Forty-five patients completed the study period of 3 months with 15 patients in each group. No patient achieved excellent (> 75%) pigmentation. Marked (50% to 75%) repigmentation was observed in 2 (13.3%), 1 (6.7%) and 4 (26.7%) patients in groups I, II and III, respectively. Moderate (25–50%) repigmentation was observed in 7 (46.7%), 5 (33.3%) and 7 (46.7%) patients in groups I, II and III, respectively. Patients with < 25% pigmentation were termed as minimal pigmentation or no response. The mean time for initial pigmentation to appear was 9.04 ± 2.0 weeks in group I, 10.18 ± 1.6 weeks in group II and 5.17 ± 2.4 weeks in group III (P < 0.01). The acquired pigmentation in the lesions was more stable in group III as compared with patients in groups II and I (P < 0.01). Side-effects in the form of atrophy and lesional burning sensations were more common in group I when compared with groups II and III (P < 0.05).
Conclusion Combined therapy appeared to give a significantly faster onset of repigmentation along with better stability of the achieved pigmentation and with lesser number of side-effects.